Johnson & Johnson (JNJ): Today's Featured Health Care Winner

The health care sector closed the day up 1.2%. Questcor Pharmaceuticals Inc ( QCOR), Tibet Pharmaceuticals Inc ( TBET), OxiGene Inc ( OXGN), and Abaxis Inc ( ABAX) were all winners today within the health care sector with Johnson & Johnson ( JNJ) being today's featured health care winner. Johnson & Johnson rose 80 cents (1.3%) to $64.49 on light volume. Throughout the day, 9.9 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 15.8 million shares.

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $177.4 billion and is part of the drugs industry. The company has a P/E ratio of 13.2, below the average drugs industry P/E ratio of 15.8 and below the S&P 500 P/E ratio of 17.7. Shares are up 3% year to date as of the close of trading on Tuesday.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Human Genome Sciences Inc ( HGSI), Spherix Inc ( SPEXD), Spherix Inc ( SPEX), and Albany Molecular Research Inc ( AMRI) were all losers within the health care sector with Vertex Pharmaceuticals ( VRTX) being today's health care sector Loser Spotlight stock.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Global Stocks Retreat as U.S.-China Trade War Intensifies

Global Stocks Retreat as U.S.-China Trade War Intensifies

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods